Chronic proton pump inhibition therapy in the diagnostic accuracy of serum pepsinogen I and gastrin concentrations to identify pernicious anaemia.

[1]  G. Berrut,et al.  Multimorbidities and Overprescription of Proton Pump Inhibitors in Older Patients , 2015, PloS one.

[2]  B. Toh.  Diagnosis and classification of autoimmune gastritis. , 2014, Autoimmunity reviews.

[3]  J. Y. Lee,et al.  Correlations Among Endoscopic, Histologic and Serologic Diagnoses for the Assessment of Atrophic Gastritis , 2014, Journal of cancer prevention.

[4]  Hyojin Park,et al.  Effects of the Addition of Mosapride to Gastroesophageal Reflux Disease Patients on Proton Pump Inhibitor: A Prospective Randomized, Double-blind Study , 2013, Journal of neurogastroenterology and motility.

[5]  A. Mangoni,et al.  Inappropriate Prescribing of Proton Pump Inhibitors in Older Patients , 2012, Drugs & Aging.

[6]  C. Ell,et al.  Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5‐year follow‐up in the LOTUS trial , 2012, Alimentary pharmacology & therapeutics.

[7]  R. Mårvik,et al.  Gastric carcinoids after long‐term use of a proton pump inhibitor , 2012, Alimentary pharmacology & therapeutics.

[8]  A. Mangoni,et al.  Inappropriate prescribing of proton pump inhibitors in older patients: effects of an educational strategy. , 2012, Drugs & aging.

[9]  F. Alderuccio,et al.  Cutting Edge Issues in Autoimmune Gastritis , 2012, Clinical Reviews in Allergy & Immunology.

[10]  S. Moestrup,et al.  Vitamin B12 transport from food to the body's cells—a sophisticated, multistep pathway , 2012, Nature Reviews Gastroenterology &Hepatology.

[11]  G. Mamikunian,et al.  A Prospective Evaluation of the Effect of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans , 2012, Pancreas.

[12]  P. Malfertheiner,et al.  Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers , 2012, Scandinavian journal of gastroenterology.

[13]  E. Lahner,et al.  Diagnosis and Management of Pernicious Anemia , 2011, Current gastroenterology reports.

[14]  A. Borobia,et al.  Overuse of PPIs in Patients at Admission, During Hospitalisation, and at Discharge in a Terciary Spanish Hospital , 2010 .

[15]  E. Lahner,et al.  Pernicious anemia: new insights from a gastroenterological point of view. , 2009, World journal of gastroenterology.

[16]  T. Sauerbruch,et al.  Effect of omeprazole treatment on plasma concentrations of the gastric peptides, xenin, gastrin and somatostatin, and of pepsinogen , 2009 .

[17]  N. Talley,et al.  Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population , 2009, Scandinavian journal of gastroenterology.

[18]  K. Haruma,et al.  Long‐term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: Five‐year prospective study in community medicine , 2007, Journal of gastroenterology and hepatology.

[19]  G. Cavestro,et al.  Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels , 2005, Fundamental & clinical pharmacology.

[20]  S. Stabler.  Clinical practice. Vitamin B12 deficiency. , 1996, The New England journal of medicine.

[21]  A. Toyonaga,et al.  Effects of omeprazole and lansoprazole on fasting and postprandial serum gastrin and serum pepsinogen A and C. , 1995, Hepato-gastroenterology.

[22]  J. Jansen,et al.  Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. , 1990, Gastroenterology.

[23]  G. Pals,et al.  Effect of single and repeated doses of oral omeprazole on gastric acid and pepsin secretion and fasting serum gastrin and serum pepsinogen I levels , 1986, Digestive Diseases and Sciences.

[24]  G. Pals,et al.  Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels. , 1984, Gastroenterology.

[25]  T. Shimosegawa,et al.  Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. , 2011, The Tohoku journal of experimental medicine.

[26]  J. Jansen,et al.  Effect of short-term omeprazole administration of serum pepsinogens in relation to fasting serum gastrin and gastric acid secretion , 2004, European Journal of Clinical Pharmacology.

[27]  G. Pals,et al.  Effect of high dose omeprazole on gastric pepsin secretion and serum pepsinogen levels in man , 2004, European Journal of Clinical Pharmacology.